GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (LTS:0LKB) » Definitions » Price-to-Free-Cash-Flow

Vanda Pharmaceuticals (LTS:0LKB) Price-to-Free-Cash-Flow : N/A (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Vanda Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-12-11), Vanda Pharmaceuticals's share price is $4.6993. Vanda Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.31. Hence, Vanda Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Vanda Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Vanda Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 1116.00. The lowest was 5.89. And the median was 16.06.

LTS:0LKB's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 36.58
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Vanda Pharmaceuticals's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.25. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.31.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Vanda Pharmaceuticals was -170.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -38.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 10.70% per year.

During the past 13 years, Vanda Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 134.20% per year. The lowest was -369.80% per year. And the median was -20.35% per year.


Vanda Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Vanda Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Price-to-Free-Cash-Flow Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.04 14.50 14.03 13.46 19.54

Vanda Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.77 19.54 - - -

Competitive Comparison of Vanda Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Vanda Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Vanda Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Vanda Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=4.6993/-0.312
=N/A

Vanda Pharmaceuticals's Share Price of today is $4.6993.
Vanda Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Vanda Pharmaceuticals  (LTS:0LKB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Vanda Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals Headlines

No Headlines